Drug updated on 3/28/2024
| Dosage Form | Cream (topical: 1%) |
| Drug Class | Quinolone antimicrobials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the topical treatment of impetigo due to Staphylococcus aureus Streptococcus pyogenes or in adult and pediatric patients 2 months of age and older.
Summary
- Ozenoxacin (Xepi) is indicated for the topical treatment of impetigo due to Staphylococcus aureus Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.
- A systematic review was conducted on a total of one document, which assessed the effectiveness of new treatments for impetigo including ozenoxacin (Xepi).
- The study included 10 trials involving 6651 participants, most clinical trials targeted nonbullous impetigo or did not specify this.
- In nonendemic settings, ozenoxacin (Xepi) appeared to have the strongest evidence base compared with retapamulin and a new minocycline formulation according to findings from these studies.
- Limited recent evidence supports the use of topical ozenoxacin (Xepi) or retapamulin for treating impetigo in nonendemic settings as per this systematic review/meta-analysis document.
- Despite its efficacy, there's an increasing need to ensure judicious use due to rising resistance against existing treatments like Xepi; development of alternative strategies is particularly important in endemic settings where systemic antibiotics are more commonly used instead.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xepi (ozenoxacin) Prescribing Information. | 2020 | FDA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Emerging treatment strategies for impetigo in endemic and nonendemic settings: a systematic review. | 2021 | Clinical Therapeutics |